Published in Br J Clin Pharmacol on November 01, 2010
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation (2015) 1.02
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int (2013) 0.88
The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty. Thrombosis (2013) 0.87
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol (2015) 0.87
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care (2013) 0.87
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet (2014) 0.86
The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb J (2014) 0.85
Rivaroxaban and hemostasis in emergency care. Emerg Med Int (2014) 0.84
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol (2012) 0.83
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J (2014) 0.79
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag (2014) 0.79
Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79
An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. J Clin Pharmacol (2014) 0.78
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther (2014) 0.77
Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care (2015) 0.77
A case of rivaroxaban associated intracranial hemorrhage. West J Emerg Med (2014) 0.77
Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Invest New Drugs (2014) 0.76
Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J (2013) 0.76
Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. J Thorac Dis (2015) 0.76
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin. Gastroenterol Res Pract (2016) 0.75
The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol (2013) 0.75
Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Ther Clin Risk Manag (2017) 0.75
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clin Appl Thromb Hemost (2016) 0.75
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75
Discovery of Intra-Abdominal Hemorrhage during Hernioplasty in a Patient Taking Rivaroxaban. Case Rep Surg (2015) 0.75
Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Ther Adv Hematol (2012) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors. Proc (Bayl Univ Med Cent) (2016) 0.75
Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis. Drug Saf Case Rep (2015) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.75
Current state of anticoagulants to treat deep venous thrombosis. Curr Cardiol Rep (2014) 0.75
What's New in Anticoagulation. Tex Heart Inst J (2016) 0.75
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med (2017) 0.75
Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis (2017) 0.75
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
The epidemiology of venous thromboembolism. Circulation (2003) 6.97
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med (2008) 6.32
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation (2006) 2.54
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40
The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol (2003) 2.33
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis (2006) 1.70
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost (2008) 1.64
Platelet dysfunction in renal failure. Semin Thromb Hemost (2004) 1.63
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol (2007) 1.51
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost (2006) 1.44
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin Pharmacokinet (2008) 1.39
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. Int J Clin Pharmacol Ther (2007) 1.34
Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs (2005) 1.01
Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. Xenobiotica (2005) 0.91
Biology of renal aging in humans. Adv Ren Replace Ther (2000) 0.89
Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost (2007) 0.89
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Early detection of acute renal failure by serum cystatin C. Kidney Int (2004) 4.62
Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology (2002) 3.16
Augmentation index is associated with cardiovascular risk. J Hypertens (2002) 3.13
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40
Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery (2006) 2.35
Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem (2004) 2.10
Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol (2010) 1.82
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation (2009) 1.82
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. Nephrol Dial Transplant (2006) 1.76
Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation (2009) 1.76
The impact of living-related kidney transplantation on the donor's life. Transplantation (2006) 1.56
Clonidine lowers blood pressure by reducing vascular resistance and cardiac output in young, healthy males. Cardiovasc Drugs Ther (2005) 1.55
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin (2008) 1.42
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol (2013) 1.40
Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffé method. Clin Chim Acta (2004) 1.39
Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol (2010) 1.34
Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci (2006) 1.31
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol (2007) 1.29
Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant (2012) 1.29
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol (2006) 1.21
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol (2006) 1.18
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol (2011) 1.17
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) (2007) 1.12
Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias. World J Surg (2004) 1.12
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol (2006) 1.10
Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol (2006) 1.09
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood (2009) 1.08
Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg (2002) 1.08
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol (2007) 1.06
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf (2008) 1.03
The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol (2013) 1.03
The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol (2005) 1.02
Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol (2011) 1.01
The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther (2013) 1.00
G-protein-coupled receptor kinase activity in human heart failure: effects of beta-adrenoceptor blockade. Cardiovasc Res (2005) 0.99
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther (2006) 0.96
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol (2014) 0.95
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects. Thromb Haemost (2009) 0.93
Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet (2012) 0.91
Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther (2005) 0.90
Aspects of quality of life through end-stage renal disease. Qual Life Res (2003) 0.90
Coronary artery bypass surgery and acute kidney injury--impact of the off-pump technique. Nephrol Dial Transplant (2008) 0.90
Laser Doppler imager (LDI) scanner and intradermal injection for in vivo pharmacology in human skin microcirculation: responses to acetylcholine, endothelin-1 and their repeatability. Br J Clin Pharmacol (2005) 0.89
Left ventricular ejection time: a potential determinant of pulse wave velocity in young, healthy males. J Hypertens (2003) 0.89
[Quality of life in patients before and after kidney transplantation]. Psychother Psychosom Med Psychol (2002) 0.89
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One (2011) 0.88
Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet (2013) 0.87
Genotype-dependent time course of lymphocyte beta 2-adrenergic receptor down-regulation. Clin Pharmacol Ther (2003) 0.87
Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation. Pharmacogenetics (2002) 0.87
Differential tissue distribution of the Invs gene product inversin. Cell Tissue Res (2005) 0.87
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment. Cancer Chemother Pharmacol (2014) 0.87
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol (2002) 0.86
Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol (2004) 0.86
Unchanged G-protein-coupled receptor kinase activity in the aging human heart. J Am Coll Cardiol (2003) 0.86
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol (2009) 0.86
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. J Clin Pharmacol (2010) 0.86
ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol (2006) 0.85
The Invs gene encodes a microtubule-associated protein. J Am Soc Nephrol (2004) 0.85
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens (2009) 0.84
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol (2012) 0.83
Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion. Clin Transplant (2002) 0.83
Improved survival in patients with type 1 diabetes mellitus after renal transplantation compared with hemodialysis: a case-control study. Transplantation (2003) 0.83
Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J Am Coll Cardiol (2002) 0.83
Central-nervous side effects of midazolam during transesophageal echocardiography. J Am Soc Echocardiogr (2002) 0.82
Noninvasive assessment of microvascular function in arterial hypertension by transthoracic Doppler harmonic echocardiography. J Am Coll Cardiol (2002) 0.82
Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel) (2012) 0.82
Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms. Biopharm Drug Dispos (2015) 0.82
Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease. J Mol Med (Berl) (2009) 0.81
Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism. Clin Pharmacol Ther (2004) 0.81
[Arterial compliance (stiffness) as a marker of subclinical atherosclerosis]. Herz (2007) 0.80
ATP protects, by way of receptor-mediated mechanisms, against hypoxia-induced injury in renal proximal tubules. J Lab Clin Med (2003) 0.80
Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant (2007) 0.80
A patient without monocytes who had pulmonary renal syndrome. Am J Kidney Dis (2004) 0.80
Serum C3 complement concentrations correlate with liver function in patients with liver cirrhosis. Hepatogastroenterology (2004) 0.80
The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism. Clin Pharmacol Ther (2006) 0.80
Membranoproliferative glomerulonephritis complicating Waldenström's macroglobulinemia. BMC Nephrol (2012) 0.80
T-cell function after interleukin-2 therapy in HIV-infected patients is correlated with serum cortisol concentrations. AIDS (2004) 0.80
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber. Thromb Res (2013) 0.79